

DAFTAR PUSTAKA

- [1] H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries," *CA. Cancer J. Clin.*, vol. 71, no. 3, pp. 209–249, May 2021, doi: 10.3322/caac.21660.
- [2] L. Anggorowati, "FAKTOR RISIKO KANKER PAYUDARA WANITA," 2013.
- [3] S. R., "Radioterapi : Dasar-Dasar Radioterapi Tata Laksana Radioterapi Penyakit Kanker," *Jkt. UI-Press*, 2007.
- [4] J. A. Bradley and N. P. Mendenhall, "Novel Radiotherapy Techniques for Breast Cancer," *Annu. Rev. Med.*, vol. 69, no. 1, pp. 277–288, Jan. 2018, doi: 10.1146/annurev-med-042716-103422.
- [5] E. J. Moding, M. B. Kastan, and D. G. Kirsch, "Strategies for optimizing the response of cancer and normal tissues to radiation," *Nat. Rev. Drug Discov.*, vol. 12, no. 7, pp. 526–542, Jul. 2013, doi: 10.1038/nrd4003.
- [6] S. M. Lumbanraja, "Pemanfaatan Partikel Proton Untuk Terapi Kanker," vol. Vol 10 No. 1, 2004.
- [7] K. Niita, H. Iwase, T. Sato, Y. Iwamoto, N. Matsuda, Y. Sakamoto, H. Nakashima, D. Mancusi, and L. Sihver, "Recent Developments of the PHITS code," *Prog. Nucl. Sci. Technol.*, vol. 1, no. 0, pp. 1–6, Feb. 2011, doi: 10.15669/pnst.1.1.
- [8] Z.-Y. Yang, P.-E. Tsai, S.-C. Lee, Y.-C. Liu, C.-C. Chen, T. Sato, and R.-J. Sheu, "Inter-comparison of Dose Distributions Calculated by FLUKA, GEANT4, MCNP, and PHITS for Proton Therapy," *EPJ Web Conf.*, vol. 153, p. 04011, 2017, doi: 10.1051/epjconf/201715304011.
- [9] W. P. Levin, H. Kooy, J. S. Loeffler, and T. F. DeLaney, "Proton beam therapy," *Br. J. Cancer*, vol. 93, no. 8, pp. 849–854, Oct. 2005, doi: 10.1038/sj.bjc.6602754.
- [10] E. T. Vitti and J. L. Parsons, "The Radiobiological Effects of Proton Beam Therapy: Impact on DNA Damage and Repair," *Cancers*, vol. 11, no. 7, p. 946, Jul. 2019, doi: 10.3390/cancers11070946.
- [11] E. B. Hug, "Proton Therapy for Primary Breast Cancer," *Breast Care*, vol. 13, no. 3, pp. 168–172, 2018, doi: 10.1159/000489893.
- [12] L. B. Stick, M. F. Jensen, S. M. Bentzen, C. Kamby, A. Y. Lundgaard, M. V. Maraldo, B. V. Offersen, J. Yu, and I. R. Vogelius, "Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy for Synchronous Bilateral Breast Cancer," *Int. J. Part. Ther.*, vol. 8, no. 4, pp. 1–13, Mar. 2022, doi: 10.14338/IJPT-21-00023.1.
- [13] G. M. Freedman, T. Li, E. Garver, K. Shillington, B. Shinkle, J. C. Tchou, O. M. Fayanju, L. Lin, and N. K. Taunk, "Five-Year Outcomes of a Phase 1/2 Trial of Accelerated Partial Breast Irradiation Using Proton Therapy for Women With Stage 0-IIA Breast Cancer," *Adv. Radiat. Oncol.*, vol. 9, no. 2, p. 101334, Feb. 2024, doi: 10.1016/j.adro.2023.101334.
- [14] F. A. Zaman, L. W. Townsend, W. C. De Wet, M. D. Looper, J. M. Brittingham, N. T. Burahmah, H. E. Spence, N. A. Schwadron, and S. S.



- Smith, "Modeling the Lunar Radiation Environment: A Comparison Among FLUKA, Geant4, HETC-HEDS, MCNP6, and PHITS," *Space Weather*, vol. 20, no. 8, p. e2021SW002895, Aug. 2022, doi: 10.1029/2021SW002895.
- [15] T. Goorley, M. James, T. Booth, F. Brown, J. Bull, L. J. Cox, J. Durkee, J. Elson, M. Fensin, R. A. Forster, *et al.*, "Features of MCNP6," *Ann. Nucl. Energy*, vol. 87, pp. 772–783, Jan. 2016, doi: 10.1016/j.anucene.2015.02.020.
- [16] Y. S. Yeom, M. C. Han, C. Choi, H. Han, B. Shin, T. Furuta, and C. H. Kim, "Computation Speeds and Memory Requirements of Mesh-Type ICRP Reference Computational Phantoms in Geant4, MCNP6, and PHITS," *Health Phys.*, vol. 116, no. 5, pp. 664–676, May 2019, doi: 10.1097/HP.0000000000000999.
- [17] C. H. Kim, Y. S. Yeom, N. Petoussi-Henss, M. Zankl, W. E. Bolch, C. Lee, C. Choi, T. T. Nguyen, K. Eckerman, H. S. Kim, M. C. Han, R. Qiu, B. S. Chung, H. Han, and B. Shin, "ICRP Publication 145: Adult Mesh-Type Reference Computational Phantoms," *Ann. ICRP*, vol. 49, no. 3, pp. 13–201, Oct. 2020, doi: 10.1177/0146645319893605.
- [18] M. N. V. Kumar, S. A. Ram, C. S. Nageswari, C. Raveena, and S. Rajan, "Early-Stage Detection of Cancer in Breast Using Artificial Intelligence," *Rev. Gest. Inov. E Tecnol.*, vol. 11, no. 2, pp. 2016–2028, Jun. 2021, doi: 10.47059/revistageintec.v11i2.1821.
- [19] dr. A. Winata, SpB (K) Onk, "Ragam Jenis Kanker Payudara yang Perlu Anda Ketahui," *Siloam Hosp.*, Oktober 2023, Accessed: Mar. 02, 2024. [Online]. Available: <https://www.siloamhospitals.com/informasi-siloam/artikel/ragam-jenis-kanker-payudara>
- [20] G. B. Rocque, C. P. Williams, K. M. Kenzik, B. E. Jackson, A. Azuero, K. I. Halilova, S. A. Ingram, M. Pisu, A. Forero, and S. Bhatia, "Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis," *Cancer*, vol. 124, no. 21, pp. 4231–4240, Nov. 2018, doi: 10.1002/cncr.31694.
- [21] A. E. Giuliano, J. L. Connolly, S. B. Edge, E. A. Mittendorf, H. S. Rugo, L. J. Solin, D. L. Weaver, D. J. Winchester, and G. N. Hortobagyi, "Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual," *CA. Cancer J. Clin.*, vol. 67, no. 4, pp. 290–303, Jul. 2017, doi: 10.3322/caac.21393.
- [22] S. Mehta, V. Suhag, M. Semwal, and N. Sharma, "Radiotherapy: Basic Concepts and Recent Advances," *Med. J. Armed Forces India*, vol. 66, no. 2, pp. 158–162, Apr. 2010, doi: 10.1016/S0377-1237(10)80132-7.
- [23] R. S. Wong, "Apoptosis in cancer: from pathogenesis to treatment," *J. Exp. Clin. Cancer Res.*, vol. 30, no. 1, p. 87, Dec. 2011, doi: 10.1186/1756-9966-30-87.
- [24] E. Weiss and C. F. Hess, "The Impact of Gross Tumor Volume (GTV) and Clinical Target Volume (CTV) Definition on the Total Accuracy in Radiotherapy: Theoretical Aspects and Practical Experiences," *Strahlenther. Onkol.*, vol. 179, no. 1, pp. 21–30, Jan. 2003, doi: 10.1007/s00066-003-0976-5.



- [25] E. Escobar-Peralta, R. Gil-García, A. A. Quezada-Bautista, and O. López-Riverol, “Helical tomotherapy: advanced radiotherapy technology,” *Rev. Médica Hosp. Gen. México*, vol. 85, no. 4, p. 9473, Dec. 2022, doi: 10.24875/HGMX.22000021.
- [26] *PEDOMAN NASIONAL PELAYANAN KEDOKTERAN TATA LAKSANA KANKER PAYUDARA*. in NOMOR HK.01.07/MENKES/414/2018. Kementerian Kesehatan RI, 2018.
- [27] S. Bisello, S. Cilla, A. Benini, R. Cardano, N. P. Nguyen, F. Deodato, G. Macchia, M. Buwenge, S. Cammelli, T. Wondemagegnehu, A. F. M. K. Uddin, S. Rizzo, A. Bazzocchi, L. Strigari, and A. G. Morganti, “Dose–Volume Constraints for Organs at Risk in Radiotherapy (CORSAIR): An ‘All-in-One’ Multicenter–Multidisciplinary Practical Summary,” *Curr. Oncol.*, vol. 29, no. 10, pp. 7021–7050, Sep. 2022, doi: 10.3390/curroncol29100552.
- [28] E. López, R. Guerrero, M. I. Núñez, R. Del Moral, M. Villalobos, J. Martínez-Galán, M. T. Valenzuela, J. A. Muñoz-Gámez, F. J. Oliver, D. Martín-Oliva, and J. M. R. De Almodóvar, “Early and late skin reactions to radiotherapy for breast cancer and their correlation with radiation-induced DNA damage in lymphocytes,” *Breast Cancer Res.*, vol. 7, no. 5, p. R690, Oct. 2005, doi: 10.1186/bcr1277.
- [29] T. Basu and N. Bhaskar, “Overview of Important ‘Organs at Risk’ (OAR) in Modern Radiotherapy for Head and Neck Cancer (HNC),” in *Cancer Survivorship*, D. Afroze, Ed., IntechOpen, 2019. doi: 10.5772/intechopen.80606.
- [30] C. Pandeli, L. M. L. Smyth, S. David, and A. W. See, “Dose reduction to organs at risk with deep-inspiration breath-hold during right breast radiotherapy: a treatment planning study,” *Radiat. Oncol.*, vol. 14, no. 1, p. 223, Dec. 2019, doi: 10.1186/s13014-019-1430-x.
- [31] M. Kirli Bolukbas, S. Karaca, V. Coskun, and E. Kocak Uzel, “Cardiac protective techniques in left breast radiotherapy: rapid selection criteria for routine clinical decision making,” *Eur. J. Med. Res.*, vol. 28, no. 1, p. 504, Nov. 2023, doi: 10.1186/s40001-023-01470-3.
- [32] H. B. Stowe, N. D. Andruska, F. Reynoso, M. Thomas, and C. Bergom, “Heart Sparing Radiotherapy Techniques in Breast Cancer: A Focus on Deep Inspiration Breath Hold,” *Breast Cancer Targets Ther.*, vol. Volume 14, pp. 175–186, Jul. 2022, doi: 10.2147/BCTT.S282799.
- [33] F. Sciacca, “Organs at risk,” in *Radiopaedia.org*, Radiopaedia.org, 2020. doi: 10.53347/rID-80650.
- [34] D. Pennington, “ALARA principles,” in *Pediatric Imaging for the Emergency Provider*, Elsevier, 2022, pp. 6–7. doi: 10.1016/B978-0-323-70849-4.00011-6.
- [35] W. D. Newhauser and R. Zhang, “The physics of proton therapy,” *Phys. Med. Biol.*, vol. 60, no. 8, pp. R155–R209, Apr. 2015, doi: 10.1088/0031-9155/60/8/R155.
- [36] V. Ferrero, J. Werner, P. Cerello, E. Fiorina, A. Vignati, F. Pennazio, and M. Rafecas, “Estimating the stopping power distribution during proton therapy:



- A proof of concept,” *Front. Phys.*, vol. 10, p. 971767, Sep. 2022, doi: 10.3389/fphy.2022.971767.
- [37] D. R. Grimes, D. R. Warren, and M. Partridge, “An approximate analytical solution of the Bethe equation for charged particles in the radiotherapeutic energy range,” *Sci. Rep.*, vol. 7, no. 1, p. 9781, Aug. 2017, doi: 10.1038/s41598-017-10554-0.
- [38] W. Demtröder, *Nuclear and Particle Physics*. in Undergraduate Lecture Notes in Physics. Cham: Springer International Publishing, 2022. doi: 10.1007/978-3-030-58313-2.
- [39] G. F. Knoll, *Radiation detection and measurement*, 4th ed. Hoboken, N.J: John Wiley, 2010.
- [40] G. Zhang, J. Wang, Y. Wang, and H. Peng, “Proton FLASH: passive scattering or pencil beam scanning?,” *Phys. Med. Biol.*, vol. 66, no. 3, p. 03NT01, Feb. 2021, doi: 10.1088/1361-6560/abd22d.
- [41] J. Perl, J. Shin, J. Schumann, B. Faddegon, and H. Paganetti, “TOPAS: an innovative proton Monte Carlo platform for research and clinical applications,” *Med. Phys.*, vol. 39, no. 11, pp. 6818–6837, Nov. 2012, doi: 10.1118/1.4758060.
- [42] O. N. Vassiliev, *Monte Carlo Methods for Radiation Transport*. in Biological and Medical Physics, Biomedical Engineering. Cham: Springer International Publishing, 2017. doi: 10.1007/978-3-319-44141-2.
- [43] T. Furuta and T. Sato, “Medical application of particle and heavy ion transport code system PHITS,” *Radiol. Phys. Technol.*, vol. 14, no. 3, pp. 215–225, Sep. 2021, doi: 10.1007/s12194-021-00628-0.
- [44] PHITS Development Team, *PHITS Ver. 3.33 User’s Manual*. JAEA.
- [45] H. Tsutsui, Y. Arakawa, Y. Ebara, A. Hashimoto, M. Hirabayashi, T. Hirayama, N. Kamiguchi, J. Kanakura, Y. Kumata, Y. Mikami, *et al.*, “Current Status of Sumitomo’s Superconducting Cyclotron Development for Proton Therapy,” *Proc. 22nd Int. Conf. Cyclotr. Their Appl.*, vol. Cyclotrons2019, p. 4 pages, 1.699 MB, 2020, doi: 10.18429/JACOW-CYCLOTRONS2019-FRA02.
- [46] X. Wang, C. Ma, R. Davis, R. R. Parikh, S. K. Jabbour, B. G. Haffty, N. J. Yue, K. Nie, and Y. Zhang, “A novel approach to Verify air gap and SSD for proton radiotherapy using surface imaging,” *Radiat. Oncol.*, vol. 14, no. 1, p. 224, Dec. 2019, doi: 10.1186/s13014-019-1436-4.
- [47] S. Rana and J. Bennouna, “Impact of Air Gap on Intensity-Modulated Proton Therapy Breast Plans,” *J. Med. Imaging Radiat. Sci.*, vol. 50, no. 4, pp. 499–505, Dec. 2019, doi: 10.1016/j.jmir.2019.09.007.

